Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLorenz Von Seidleinen_US
dc.contributor.authorSarah Auburnen_US
dc.contributor.authorFe Espinoen_US
dc.contributor.authorDennis Shanksen_US
dc.contributor.authorQin Chengen_US
dc.contributor.authorJames McCarthyen_US
dc.contributor.authorKevin Bairden_US
dc.contributor.authorCatherine Moyesen_US
dc.contributor.authorRosalind Howesen_US
dc.contributor.authorDidier Ménarden_US
dc.contributor.authorGermana Banconeen_US
dc.contributor.authorAri Winasti-Satyahrahaen_US
dc.contributor.authorLasse S. Vestergaarden_US
dc.contributor.authorJustin Greenen_US
dc.contributor.authorGonzalo Domingoen_US
dc.contributor.authorShunmay Yeungen_US
dc.contributor.authorRic Priceen_US
dc.contributor.otherMenzies School of Health Researchen_US
dc.contributor.otherAustralian Army Malaria Instituteen_US
dc.contributor.otherUniversity of Queenslanden_US
dc.contributor.otherEijkman-Oxford Clinical Research Uniten_US
dc.contributor.otherUniversity of Oxforden_US
dc.contributor.otherInstitut Pasteur du Cambodgeen_US
dc.contributor.otherShoklo Malaria Research Uniten_US
dc.contributor.otherThe World Health Organization Regional Office for the Western Pacific philippinesen_US
dc.contributor.otherGlaxoSmithKline plc.en_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.identifier.citationMalaria Journal. Vol.12, No.1 (2013)en_US
dc.description.abstractThe diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency is a crucial aspect in the current phases of malaria control and elimination, which will require the wider use of 8-aminoquinolines for both reducing Plasmodium falciparum transmission and achieving the radical cure of Plasmodium vivax. 8-aminoquinolines, such as primaquine, can induce severe haemolysis in G6PD-deficient individuals, potentially creating significant morbidity and undermining confidence in 8-aminoquinoline prescription. On the other hand, erring on the side of safety and excluding large numbers of people with unconfirmed G6PD deficiency from treatment with 8-aminoquinolines will diminish the impact of these drugs. Estimating the remaining G6PD enzyme activity is the most direct, accessible, and reliable assessment of the phenotype and remains the gold standard for the diagnosis of patients who could be harmed by the administration of primaquine. Genotyping seems an unambiguous technique, but its use is limited by cost and the large range of recognized G6PD genotypes. A number of enzyme activity assays diagnose G6PD deficiency, but they require a cold chain, specialized equipment, and laboratory skills. These assays are impractical for care delivery where most patients with malaria live. Improvements to the diagnosis of G6PD deficiency are required for the broader and safer use of 8-aminoquinolines to kill hypnozoites, while lower doses of primaquine may be safely used to kill gametocytes without testing. The discussions and conclusions of a workshop conducted in Incheon, Korea in May 2012 to review key knowledge gaps in G6PD deficiency are reported here. © 2013 von Seidlein et al.; licensee BioMed Central Ltd.en_US
dc.rightsMahidol Universityen_US
dc.subjectImmunology and Microbiologyen_US
dc.titleReview of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: A workshop reporten_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.